Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

BACKGROUND AND AIMS: Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn’s disease. This open-label extension investigated the long-term safety, pharmacokinetics, immunogenicity and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrante, Marc, Feagan, Brian G, Panés, Julián, Baert, Filip, Louis, Edouard, Dewit, Olivier, Kaser, Arthur, Duan, W Rachel, Pang, Yinuo, Lee, Wan-Ju, Gustafson, Dawn, Liao, Xiaomei, Wallace, Kori, Kalabic, Jasmina, D’Haens, Geert R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684487/
https://www.ncbi.nlm.nih.gov/pubmed/34077509
http://dx.doi.org/10.1093/ecco-jcc/jjab093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684487/
https://www.ncbi.nlm.nih.gov/pubmed/34077509
http://dx.doi.org/10.1093/ecco-jcc/jjab093

Ejemplares similares